IL-17 inhibition in axial spondyloarthritis: current and future perspectives

References

• Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73–84.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewe R, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777–783.
   PubMed Web of Science ®Google Scholar
• Ranganathan V, Gracey E, Brown MA, et al. Pathogenesis of ankylosing spondylitis - recent advances and future directions. Nat Rev Rheumatol. 2017;13(6):359–367.
   PubMed Web of Science ®Google Scholar
• Stolwijk C, Boonen A, van Tubergen A, et al. Epidemiology of spondyloarthritis. Rheum Dis Clin North Am. 2012;38(3):441–476.
   PubMed Web of Science ®Google Scholar
• Bowness P. HLA-B27. Annu Rev Immunol. 2015;33:29–48.
   PubMed Web of Science ®Google Scholar
• Simone D, Al Mossawi MH, Bowness P. Progress in our understanding of the pathogenesis of ankylosing spondylitis. Rheumatology. 2018;57(suppl_6):vi4–vi9.
   PubMedGoogle Scholar
• Pedersen SJ, Maksymowych WP. Beyond the TNF-α inhibitors: new and emerging targeted therapies for patients with axial spondyloarthritis and their relation to pathophysiology. Drugs. 2018;78(14):1397–1418.
   PubMed Web of Science ®Google Scholar
• De Vos M, Mielants H, Cuvelier C, et al. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology. 1996;110(6):1696–1703.
   PubMed Web of Science ®Google Scholar
• Gill T, Asquith M, Rosenbaum JT, et al. The intestinal microbiome in spondyloarthritis. Curr Opin Rheumatol. 2015;27(4):319–325.
   PubMed Web of Science ®Google Scholar
• Cortes A, Hadler J, Pointon JP, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet. 2013;45(7):730–738.
   PubMed Web of Science ®Google Scholar
• Han Q, Das S, Hirano M, et al. Characterization of lamprey IL-17 family members and their receptors. J Immunol. 2015;195(11):5440–5451.
   PubMed Web of Science ®Google Scholar
• Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11(10):763–776.
   PubMed Web of Science ®Google Scholar
• Veldhoen M. Interleukin 17 is a chief orchestrator of immunity. Nat Immunol. 2017;18(6):612–621.
   PubMed Web of Science ®Google Scholar
• Rouvier E, Luciani MF, Mattei MG, et al. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol. 1993;150(12):5445–5456.
   PubMed Web of Science ®Google Scholar
• Yao Z, Painter SL, Fanslow WC, et al. Human IL-17: a novel cytokine derived from T cells. J Immunol. 1995;155(12):5483–5486.
   PubMed Web of Science ®Google Scholar
• Moseley TA, Haudenschild DR, Rose L, et al. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003;14(2):155–174.
   PubMed Web of Science ®Google Scholar
• Chang SH, Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. 2007;17(5):435–440.
   PubMed Web of Science ®Google Scholar
• Taams LS, Steel KJA, Srenathan U, et al. IL-17 in the immunopathogenesis of spondyloarthritis. Nat Rev Rheumatol. 2018;14(8):453–466.
   PubMed Web of Science ®Google Scholar
• Jandus C, Bioley G, Rivals JP, et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum. 2008;58(8):2307–2317.
   PubMed Web of Science ®Google Scholar
• Al-Mossawi MH, Chen L, Fang H, et al. Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis. Nat Commun. 2017;8(1):1510.
   PubMedGoogle Scholar
• Liang Y, Pan HF, Ye DQ. Tc17 cells in immunity and systemic autoimmunity. Int Rev Immunol. 2015;34(4):318–331.
   PubMed Web of Science ®Google Scholar
• Steel K, Wu S-Y, Srenathan U, et al. O016 Synovial IL-17+ CD8+ T cells are a pro-inflammatory tissue resident population enriched in spondyloarthritis. Ann Rheum Dis. 2018;77(Suppl 1):A8–A9.
   Google Scholar
• Kenna TJ, Davidson SI, Duan R, et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive gamma/delta T cells in patients with active ankylosing spondylitis. Arthritis Rheum. 2012;64(5):1420–1429.
   PubMed Web of Science ®Google Scholar
• Gracey E, Qaiyum Z, Almaghlouth I, et al. IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Ann Rheum Dis. 2016;75(12):2124–2132.
   PubMed Web of Science ®Google Scholar
• Hayashi E, Chiba A, Tada K, et al. Involvement of mucosal-associated invariant T cells in ankylosing spondylitis. J Rheumatol. 2016;43(9):1695–1703.
   PubMed Web of Science ®Google Scholar
• Yoshiga Y, Goto D, Segawa S, et al. Invariant NKT cells produce IL-17 through IL-23-dependent and -independent pathways with potential modulation of Th17 response in collagen-induced arthritis. Int J Mol Med. 2008;22(3):369–374.
   PubMed Web of Science ®Google Scholar
• Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheumatism. 2012;64(1):99–109.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Guggino G, Rizzo A, et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis. 2015;74(9):1739–1747.
   PubMed Web of Science ®Google Scholar
• Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9(8):556–567.
   PubMed Web of Science ®Google Scholar
• Toy D, Kugler D, Wolfson M, et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol. 2006;177(1):36–39.
   PubMed Web of Science ®Google Scholar
• Kuestner RE, Taft DW, Haran A, et al. Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol. 2007;179(8):5462–5473.
   PubMed Web of Science ®Google Scholar
• Gu C, Wu L, Li X. IL-17 family: cytokines, receptors and signaling. Cytokine. 2013;64(2):477–485.
   PubMed Web of Science ®Google Scholar
• Lubberts E. The IL-23–IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol. 2015;11(7):415–429.
   PubMed Web of Science ®Google Scholar
• Lee JS, Tato CM, Joyce-Shaikh B, et al. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. Immunity. 2015;43(4):727–738.
   PubMed Web of Science ®Google Scholar
• Li Z, Brown MA. Progress of genome-wide association studies of ankylosing spondylitis. Clin Transl Immunology. 2017;6(12):e163.
   PubMedGoogle Scholar
• Vieira-Sousa E, van Duivenvoorde LM, Fonseca JE, et al. Review: animal models as a tool to dissect pivotal pathways driving spondyloarthritis. Arthritis Rheumatol. 2015;67(11):2813–2827.
   PubMed Web of Science ®Google Scholar
• Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther. 2005;7(1):29–37.
   PubMed Web of Science ®Google Scholar
• Wendling D. The gut in spondyloarthritis. Joint Bone Spine. 2016;83(4):401–405.
   PubMed Web of Science ®Google Scholar
• Appel H, Maier R, Wu P, et al. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther. 2011;13(3):R95.
   PubMed Web of Science ®Google Scholar
• Jansen DT, Hameetman M, van Bergen J, et al. IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities. Rheumatology (Oxford). 2015;54(4):728–735.
   PubMed Web of Science ®Google Scholar
• Wendling D, Cedoz JP, Racadot E, et al. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine. 2007;74(3):304–305.
   PubMed Web of Science ®Google Scholar
• Taylan A, Sari I, Kozaci DL, et al. Evaluation of the T helper 17 axis in ankylosing spondylitis. Rheumatol Int. 2012;32(8):2511–2515.
   PubMed Web of Science ®Google Scholar
• Chen WS, Chang YS, Lin KC, et al. Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis. J Chin Med Assoc. 2012;75(7):303–308.
   PubMed Web of Science ®Google Scholar
• Xueyi L, Lina C, Zhenbiao W, et al. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-alpha therapy. J Clin Immunol. 2013;33(1):151–161.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978–991.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis — results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329–1339.
   PubMed Web of Science ®Google Scholar
• Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9906):1705–1713.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Borah B, Braun J, et al. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis. 2016;75(2):408–412.
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–2548.
   PubMed Web of Science ®Google Scholar
• Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017;19(1):285.
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Wagner U, Dokoupilova E, et al. Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study. Rheumatol Ther. 2018;5(2):447–462.
   PubMed Web of Science ®Google Scholar
• Deodhar AA, Dougados M, Baeten DL, et al. Effect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: A phase III randomized trial (MEASURE 1). Arthritis Rheumatol. 2016;68(12):2901–2910.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Deodhar A, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017;76(6):1070–1077.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Kivitz AJ, Deodhar AA, et al. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the phase 3 MEASURE 1 trial. Clin Exp Rheumatol. 2018;36(1):50–55.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Deodhar A, et al. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology (Oxford). 2018. DOI:10.1093/rheumatology/key375.
   Google Scholar
• X BJ B, Deodhar AA, Poddubnyy D, et al. Long-term evaluation of secukinumab in ankylosing spondylitis: 5 year efficacy and safety results from a phase 3 trial [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). [cited 2018 Dec 18]. Available from: https://acrabstractsorg/abstract/long-term-evaluation-of-secukinumab-in-ankylosing-spondylitis-5-year-efficacy-and-safety-results-from-a-phase-3-trial/
   Google Scholar
• Sieper J, Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 study. Ann Rheum Dis. 2017;76(3):571–592.
   PubMed Web of Science ®Google Scholar
• Marzo-Ortega H, Sieper J, Kivitz A, et al. Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results From a phase III study. Arthritis Care Res (Hoboken). 2017;69(7):1020–1029.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Conaghan PG, Kvien TK, et al. Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study. Clin Exp Rheumatol. 2019;37(2):260–269.
   PubMed Web of Science ®Google Scholar
• Marzo-Ortega H, Sieper J, Kivitz A, et al. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. RMD Open. 2017;3(2):e000592.
   PubMed Web of Science ®Google Scholar
• Marzo-Ortega H, Sieper J, Kivitz A, et al. SAT0283 Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 4-year results from the phase iii trial, measure 2. Ann Rheum Dis. 2018;77(Suppl 2):1005.
   Google Scholar
• Braun J, Deodhar A, Landewe R, et al. Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies. RMD Open. 2018;4(2):e000749.
   PubMed Web of Science ®Google Scholar
• Emery P, Van Keep M, Beard S, et al. Cost effectiveness of secukinumab for the treatment of active ankylosing spondylitis in the UK. PharmacoEconomics. 2018;36(8):1015–1027.
   PubMed Web of Science ®Google Scholar
• Colombo GL, Di Matteo S, Martinotti C, et al. Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative. Clinicon Econ Outcomes Res. 2018;10:477–491.
   PubMed Web of Science ®Google Scholar
• Purmonen T, Tormalehto S, Wahlman H, et al. Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitis. J Med Econ. 2019;22(2):151–157.
   PubMed Web of Science ®Google Scholar
• Goeree R, Chiva-Razavi S, Gunda P, et al. Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective. J Med Econ. 2019;22(1):45–52.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Braun J, Deodhar A, et al. Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. Rheumatology (Oxford). 2018;58(3):388–400.
   Web of Science ®Google Scholar
• Poddubnyy D, Sieper J. Mechanism of new bone formation in axial spondyloarthritis. Curr Rheumatol Rep. 2017;19(9):55.
   PubMed Web of Science ®Google Scholar
• Braun J, Haibel H, de Hooge M, et al. SAT0259 Low rate of spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison. Ann Rheum Dis. 2018;77(Suppl 2):992–993.
   Google Scholar
• Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39–50.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441–2451.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: 16 week results of a phase 3 randomized, double-blind, placebo controlled trial in patients with prior inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599–611.
   Web of Science ®Google Scholar
• Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991–1001.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Gensler LS, Deodhar A, et al. LB0001 Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2018;77(Suppl 2):70.
   PubMedGoogle Scholar
• Papp KA, Reid C, Foley P, et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol. 2012;132(10):2466–2469.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014;370(24):2295–2306.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Papp KA, Marangell LB, et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78(1):81–89.e5.
   PubMed Web of Science ®Google Scholar
• Mazurov V, Erdes S, Kunder E, et al. OP0028 Efficacy and safety of bcd-085, a novel il-17 inhibitor, in ankylosing spondylitis. results of phase 2 clinical study. Ann Rheum Dis. 2018;77(Suppl2):64.
   Google Scholar